Comment on: "EU's new pharmacovigilance legislation: considerations for biosimilars"

Drug Saf. 2014 Feb;37(2):123-4. doi: 10.1007/s40264-013-0128-5.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Biosimilar Pharmaceuticals / standards*
  • Drug-Related Side Effects and Adverse Reactions*
  • Humans
  • Pharmacovigilance*

Substances

  • Biosimilar Pharmaceuticals